Đang chuẩn bị liên kết để tải về tài liệu:
Intertumoral heterogeneity in patientspecific drug sensitivities in treatmentnaïve glioblastoma

A major barrier to effective treatment of glioblastoma (GBM) is the large intertumoral heterogeneity at the genetic and cellular level. In early phase clinical trials, patient heterogeneity in response to therapy is commonly observed; however, how tumor heterogeneity is reflected in individual drug sensitivities in the treatment-naïve glioblastoma stem cells (GSC) is unclear. | Intertumoral heterogeneity in patientspecific drug sensitivities in treatmentnaïve glioblastoma